ARFGEF2

Across TCGA pan-cancer cohorts, ARFGEF2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of ARFGEF2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ARFGEF2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ARFGEF2 is over-expressed in tumor, although a few such as CCRCC and PDAC show the opposite, repressed pattern.

CCRCC, LUAD, and COAD are the cancer types where ARFGEF2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARFGEF2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	−0.396	<.001	11	view →
LUAD	Male	II,III,IV	+0.343	<.001	9	view →
COAD	Male	III,IV	+0.296	<.001	9	view →
PDAC	Male	All	−0.716	<.001	6	view →
LSCC	All	All	+0.106	<.001	6	view →
HNSC	All	II,III,IV	+0.126	.007	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

ARFGEF2–CCRCC

Open the CCRCC breakdown →